These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Sai-Hong Ignatius Ou and Randall F. Holcombe. Ou SH; Holcombe RF Drugs; 2007; 67(4):611-2. PubMed ID: 17352521 [No Abstract] [Full Text] [Related]
5. Capecitabine in advanced gastric or oesophagogastric cancer: a viewpoint by Yoon-Koo Kang. Kang YK Drugs; 2007; 67(4):611-2. PubMed ID: 17352520 [No Abstract] [Full Text] [Related]
6. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. Wagstaff AJ; Ibbotson T; Goa KL Drugs; 2003; 63(2):217-36. PubMed ID: 12515569 [TBL] [Abstract][Full Text] [Related]
7. Capecitabine: a review. Walko CM; Lindley C Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604 [TBL] [Abstract][Full Text] [Related]
9. Capecitabine in the treatment of advanced gastric cancer. Lee JL; Kang YK Future Oncol; 2008 Apr; 4(2):179-98. PubMed ID: 18407732 [TBL] [Abstract][Full Text] [Related]
10. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. McGavin JK; Goa KL Drugs; 2001; 61(15):2309-26. PubMed ID: 11772141 [TBL] [Abstract][Full Text] [Related]
11. Emerging role of capecitabine in gastric cancer. Comella P; Franco L; Casaretti R; de Portu S; Menditto E Pharmacotherapy; 2009 Mar; 29(3):318-30. PubMed ID: 19249950 [TBL] [Abstract][Full Text] [Related]
12. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569 [TBL] [Abstract][Full Text] [Related]
13. Capecitabine for the treatment of advanced gastric cancer. Norman G; Soares M; Peura P; Rice S; Suh D; Wright K; Sculpher M; Eastwood A Health Technol Assess; 2010 Oct; 14(Suppl. 2):11-7. PubMed ID: 21047486 [TBL] [Abstract][Full Text] [Related]
14. Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Ajani J Cancer; 2006 Jul; 107(2):221-31. PubMed ID: 16770784 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Okines AFC; Norman AR; McCloud P; Kang YK; Cunningham D Ann Oncol; 2009 Sep; 20(9):1529-1534. PubMed ID: 19474114 [TBL] [Abstract][Full Text] [Related]
16. Rational development of capecitabine. Venturini M Eur J Cancer; 2002 Feb; 38 Suppl 2():3-9. PubMed ID: 11841929 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of capecitabine in breast cancer. Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520 [TBL] [Abstract][Full Text] [Related]
18. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis. Ter Veer E; Creemers A; de Waal L; van Oijen MGH; van Laarhoven HWM Int J Cancer; 2018 Jul; 143(2):438-448. PubMed ID: 29451302 [TBL] [Abstract][Full Text] [Related]